apoH Antibody (C-2): sc-515677

apoH Antibody (C-2) is a mouse monoclonal IgG2b kappa light chain antibody that detects apoH protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). anti-apoH antibody (C-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Human apolipoprotein H (apoH), also known as β 2-glycoprotein I, activated protein C binding protein, or APC inhibitor, is a five-domain plasma membrane-adhesion protein that plays a crucial role in several physiological processes, including blood coagulation and immune response. apoH is primarily synthesized by hepatocytes and is found in the bloodstream associated with plasma lipoproteins, where apoH exhibits a genetically determined structural polymorphism with three alleles (apoH1, apoH2, and apoH3). apoH is involved in the clearance of apoptotic bodies from circulation, which is vital for maintaining tissue homeostasis and preventing autoimmune responses. apoH acts as a cofactor for the binding of serum auto-antibodies in antiphospholipid syndrome, linking apoH to conditions such as thrombosis, lupus erythematosus, and recurrent fetal loss. apoH gene is located on human chromosome 17q23-24, and apoH′s ability to inhibit the translocation of cholesterol from extracellular pools to macrophages suggests a protective role against atherosclerosis by reducing cellular cholesterol accumulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

apoH Antibody (C-2) References:

1. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.  |  Müller, HJ., et al. 2002. Int J Clin Pharmacol Ther. 40: 575-7. PMID: 12503820
2. The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.  |  Müller, HJ., et al. 2003. Int J Clin Pharmacol Ther. 41: 598-9. PMID: 14692710
3. APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome.  |  Castro, A., et al. 2010. Atherosclerosis. 209: 201-5. PMID: 19878946
4. Exosome-Contained APOH Associated With Antiphospholipid Syndrome.  |  Tan, Y., et al. 2021. Front Immunol. 12: 604222. PMID: 34040601
5. Apo-H (beta-2-glycoprotein) intact N-glycan analysis by MALDI-TOF-MS using sialic acid derivatization.  |  Javeed, R., et al. 2021. Anal Bioanal Chem. 413: 7441-7449. PMID: 34686894
6. The association of APOH and NCF1 polymorphisms on susceptibility to recurrent pregnancy loss in women with antiphospholipid syndrome.  |  Deng, X., et al. 2023. J Assist Reprod Genet. 40: 1703-1712. PMID: 37243946
7. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.  |  Nimpf, J., et al. 1987. Atherosclerosis. 63: 109-14. PMID: 3827975
8. Fructus arctii mitigates diabetic nephropathy via the Apoh/PPAR-γ pathway.  |  Zhang, N., et al. 2025. Mol Immunol. 181: 18-28. PMID: 40056629
9. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.  |  Mross, K., et al. 1996. Cancer Chemother Pharmacol. 38: 217-24. PMID: 8646795
10. Population distributions of APOE, APOH, and APOA4 polymorphisms and their relationships with quantitative plasma lipid levels among the Evenki herders of Siberia.  |  Kamboh, MI., et al. 1996. Hum Biol. 68: 231-43. PMID: 8838914

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-apoH Antibody (C-2) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-apoH Antibody (C-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

apoH Antibody (C-2) Specifications

Alternate Product Name: apoH

Product Clone Name: C-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 182-340

Epitope Target: apoH

Epitope Species: human

Product Reactivity/Detection: apoH

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for apoH Antibody (C-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin